Sign inJoin waitlistJoin the waitlist

Jian Campian

Professor of Oncology · Mayo Clinic College of Medicine and Science

Credentials: · · · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Neuro-Oncology Johns Hopkins Hospital
2003–2004
Hematology and Medical Oncology Johns Hopkins Hospital
2000–2003
Postdoctoral Training University of Louisville
Internal Medicine
Long Island Jewish Medical Center - Northwell Health
1997–2000
Tianjin Medical University
1993–1997

Research

A draft sequence of the rice genome (Oryza sativa L. ssp. indica)
Science · 2002 · 1,889 citations
The genome of the cucumber, Cucumis sativus L
Nature Genetics · 2009 · 878 citations
Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus
Nature Genetics · 2009 · 810 citations

Jiayi Huang
23 papers
Ugur Sener
22 papers
Albert Kim
18 papers · 6 as a resident
Sani Kizilbash
14 papers
Milan Chheda
13 papers · 12 as a resident
Omar Butt
12 papers · 4 as a fellow
SG
Stuart Grossman
12 papers
Terry Burns
12 papers
Michael Ruff
11 papers
GA
George Ansstas
10 papers
Joon Uhm
10 papers
Tanner Johanns
10 papers

Grants

NT-I7, a Novel Long-Acting Interleukin-7, in Combination with Anti-PD-1 Checkpoint Blockade for the Treatment of Glioablastoma
National Cancer Institute · R01
Contact PI · $1.3M · Mayo Clinic Rochester
2025–2029

Clinical trials

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Principal investigator · Recruiting · Phase 2
Mayo Clinic
2026–2034
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Principal investigator · Recruiting · Phase 2
Academic and Community Cancer Research United
2024–2030
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
Principal investigator · Recruiting · Phase 2
Mayo Clinic
2023–2028
Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Increase Lymphocyte Counts and Enhance Immune Clearance of SARS-CoV-2 (COVID-19)
Principal investigator · Withdrawn · Phase 1
Washington University School of Medicine
2021–2022